Eli Lilly’s investigational obesity pill led to less weight loss in a late-stage trial than the reductions seen with injectable treatments on the market, results that weaken its competitiveness as one of Lilly’s most-anticipated candidates. After 72 weeks, patients taking the highest dose of the therapy, called orforglipron, experienced 11.2% weight loss, when analyzing all…
Sales of Danish drugmaker Novo Nordisk‘s Wegovy and U.S. rival Eli Lilly’s Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on Thursday. Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world’s most populous nation….
Novo Nordisk said Tuesday it was tapping Maziar Mike Doustdar, its head of international operations, as its new CEO, amid a broader leadership shakeup across the company. Novo’s current CEO, Lars Fruergaard Jørgensen, announced he was stepping down in May, as the company faced a tumbling share price and growing competition from Eli Lilly in the…